CGEM
Cullinan Therapeutics, Inc.
NASDAQ · USHealthcareMedical - Pharmaceuticals
$17.50-1.07%
Price as of Jul 20, 2026
CGEM financials
Cullinan Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $306.0K | $0.00 | $0.00 |
| Gross profit | $0.00 | -$306.0K | $0.00 | $0.00 |
| Operating expenses | $241.6M | $196.6M | $191.1M | -$144.6M |
| Operating income | -$241.6M | -$196.9M | -$191.1M | $144.6M |
| Net income | -$219.9M | -$167.4M | -$153.2M | $111.2M |
| EBITDA | -$219.6M | -$167.2M | -$190.3M | -$132.0M |
| Basic EPS | $-3.72 | $-3.11 | $-3.69 | $2.46 |
| Diluted EPS | $-3.72 | $-3.11 | $-3.69 | $2.38 |
| Balance sheet | ||||
| Cash & equivalents | $88.3M | $83.0M | $98.4M | $156.2M |
| Total assets | $448.4M | $621.8M | $484.2M | $561.1M |
| Total liabilities | $39.6M | $31.5M | $30.3M | $26.1M |
| Stockholders’ equity | $408.7M | $590.3M | $453.7M | $535.0M |
| Total debt | $2.7M | $2.2M | $3.6M | $5.2M |
| Net debt | -$85.6M | -$80.9M | -$94.8M | -$151.0M |
| Cash flow | ||||
| Operating cash flow | -$175.8M | -$145.3M | -$134.3M | -$126.7M |
| Capital expenditure | -$49.0K | $0.00 | -$208.0K | -$1.1M |
| Free cash flow | -$175.8M | -$145.3M | -$134.5M | -$127.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |